A nationwide 104 weeks real-world study of dupilumab in adults with atopic dermatitis: ineffectiveness in head-and-neck dermatitis.

Ida VittrupN S KroghH H P LarsenJ ElberlingLone SkovK S IblerG B E JemecC G MortzR O BachC Bindslev-JensenM G DalagerAlexander Egeberg Tove AgnerM DeleuranC VestergaardJacob Pontoppidan Thyssen

Published in: Journal of the European Academy of Dermatology and Venereology : JEADV (2023)

While two-year drug survival was 86%, dupilumab was unable to effectively treat AD in the head-and-neck area, and conjunctivitis was found in 25% of patients.

Keyphrases

atopic dermatitis
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
emergency department
cross sectional
patient reported outcomes
free survival